Inan, CihanVarol, Fusun GulizarErzincan, Selen GursoyUzun, IsilSutcu, HavvaSayin, N. Cenk2024-06-122024-06-1220181476-70581476-4954https://doi.org/10.1080/14767058.2017.1351536https://hdl.handle.net/20.500.14551/21137Introduction: To compare the predictive effectiveness levels of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and the PROK1/PAPP-A ratio in the first trimester for preeclampsia (PE), foetal growth restriction (FGR), gestational diabetes mellitus (GDM) and spontaneous preterm birth (SPB).Materials and methods: A total of randomly selected 162 pregnant women were included. Peripheral blood samples were obtained between 11(0/7) and 13(6/7) gestational weeks (GWs). All women were followed throughout the pregnancy and classified into five groups as having PE, FGR, GDM, SPB and uncomplicated pregnancies. The cut-off levels of the markers were identified to predict adverse outcomes.Results: PROK1 predicted PE with 83.3% sensitivity, 85.7% specificity at a value of >293.4pg/mL; at a value of >260.2pg/mL, PROK1 predicted FGR with 85.7% sensitivity, 72.5% specificity in the first trimester. The area under receiver operating characteristic (ROC) curve of PAPP-A was lower than that of PROK1 and PROK1/PAPP-A in differentiating PE and FGR from the uncomplicated group (p<.001). PROK1 levels and the PROK1/PAPP-A ratios in the SPB and GDM groups were lower than in the uncomplicated group (p<.01).Conclusions: Elevated PROK1 in the first trimester is a more effective marker than PAPP-A in the prediction of PE and FGR. Lower PROK1 levels are associated with the development of SPB and GDM.en10.1080/14767058.2017.1351536info:eu-repo/semantics/closedAccessFoetal Growth RetardationGestational Diabetes MellitusPreeclampsiaPreterm BirthProkinecin 1Intrauterine Growth RestrictionEg-VegfPreterm Delivery1st-TrimesterPreeclampsiaReceptorsCellsBirthRiskTermArticle312026852692Q3WOS:0004363372000062-s2.0-8502439763528675948Q2